Drug for rare childhood cancer may help prevent prostate cancer spread
April 30th, 2011 - 2:16 pm ICT by ANIWashington, April 30 (ANI): A new study has found that a drug developed to treat Ewing’s Sarcoma, a rare childhood cancer, may also help prevent human prostate cancer from spreading.
Researchers at Georgetown Lombardi Comprehensive Cancer Center have said that if the drug continues to work well - as they found in their lab- in further laboratory and pre-clinical studies, it may be the first prostate cancer drug specifically designed to stop cancer spread, or metastasis.
“This agent does not kill prostate cancer cells, but limits their ability to spread, which could be hugely beneficial in patients,” said the study’s lead investigator, Aykut Uren, an associate professor at Georgetown Lombardi.
The agent, YK-4 279, was designed in the GUMC Drug Discovery Program, directed by Milton Brown, a co-author on the paper.
YK-4 279 is also being investigated for the treatment of Ewing’s sarcoma and is expected to move quickly into a clinical study.
Recent research has shown that 40 to 70 percent of prostate cancer cells express novel proteins when normal genes such as ETV1 and ERG break off from a chromosome and fuse in to a new location. These new genes produce proteins that push prostate cancer cells to become more aggressive and spread.
Noting that a similar fusion gene produces Ewing’s sarcoma, the researchers decided to check if their drug would work in prostate cancer cells.
They applied the agent to prostate cancer cells with chromosomal translocations that expressed either an ERG protein or an ETV1 protein and found that the YK-4 279 did inhibit functions of these proteins, which reduced their motility and invasiveness.
The finding was published online April 29 in PLoS ONE. (ANI)
- Arsenic-based agent shuts down hard-to-treat cancers - Dec 23, 2010
- New method to block protein fusion behind rare cancer unveiled - Jul 06, 2009
- Flower power may cut resistance to breast cancer drug tamoxifen - Feb 17, 2010
- Gene fusion is the 'smoking gun' in the development of prostate cancer: Study - May 19, 2010
- New drugs to kill cancers minus side-effects - May 21, 2012
- Potential driver of some aggressive prostate cancers found - Apr 05, 2011
- First molecule that blocks key component of cancer genes' on-off switch created - Sep 25, 2010
- Soy-based drug 'may stop prostate cancer spread' - Nov 09, 2010
- Silencing 'hedgehog' molecule halts cancer - Jun 06, 2011
- Cell that could be 'mother' of all prostate tumours identified - Jul 30, 2010
- How 'triggering event' in cancer occurs - Oct 30, 2009
- Slowing down prostate cancer by starving its cells - Nov 03, 2011
- Molecular predictor of metastatic prostate cancer identified - Feb 03, 2011
- Mechanism that turns healthy cells into prostate cancer cells discovered - Dec 03, 2010
- Indian-origin scientist discovers cold virus that kills cancer - Oct 21, 2010
Tags: aykut, cancer drug, chromosome, co author, comprehensive cancer center, drug discovery program, etv1, ewing, fusion gene, human prostate cancer, lombardi comprehensive cancer center, milton brown, motility, new location, novel proteins, plos one, prostate cancer, prostate cancer cells, rare childhood cancer, translocations